Literature DB >> 16547155

VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma.

Claudio R Santos1, María Rodríguez-Pinilla, Francisco M Vega, José L Rodríguez-Peralto, Sandra Blanco, Ana Sevilla, Alberto Valbuena, Teresa Hernández, André J van Wijnen, Fengzhi Li, Enrique de Alava, Montserrat Sánchez-Céspedes, Pedro A Lazo.   

Abstract

The vaccinia-related kinase (VRK) proteins are a new family with three members in the human kinome. The VRK1 protein phosphorylates several transcription factors and has been postulated to be involved in regulation of cell proliferation. In normal squamous epithelium, VRK1 is expressed in the proliferation area. Because VRK1 can stabilize p53, the expression of the VRK1 protein was analyzed in the context of the p53 pathway and the proliferation phenotype in a series of 73 head and neck squamous cell carcinomas. VRK1 protein level positively correlated with p53 response proteins, particularly hdm2 and p21. The VRK1 protein also correlated positively with several proteins associated with proliferation, such as cyclin-dependent kinase 2 (CDK2), CDK6, cdc2, cyclins B1 and A, topoisomerase II, survivin, and Ki67. The level of VRK1 protein behaves like a proliferation marker in this series of head and neck squamous cell carcinomas. To identify a possible regulatory role for VRK1 and because it regulates gene transcription, the promoters of two genes were studied, CDK2 and SURVIVIN, whose proteins correlated positively with VRK1. VRK1 increases the activity of both the CDK2 and SURVIVIN gene promoters. The expression of VRK1 was analyzed in the context of regulators of the G1-S transition. VRK1 protein levels increase in response to E2F1 and are reduced by retinoblastoma and p16. These data suggest that VRK1 might play a role in cell cycle regulation and is likely to represent the beginning of a new control mechanism of cell cycle, particularly late in the G1-S phase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547155     DOI: 10.1158/1541-7786.MCR-05-0212

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  42 in total

1.  Macro histone H2A1.2 (macroH2A1) protein suppresses mitotic kinase VRK1 during interphase.

Authors:  Wanil Kim; Goutam Chakraborty; Sangjune Kim; Joon Shin; Choon-Ho Park; Min-Woo Jeong; Nagakumar Bharatham; Ho Sup Yoon; Kyong-Tai Kim
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

Review 2.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

3.  VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.

Authors:  Isabel F Fernández; Sandra Blanco; José Lozano; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

4.  p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop.

Authors:  Alberto Valbuena; Francisco M Vega; Sandra Blanco; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 5.  Biomarkers of head and neck cancer, tools or a gordian knot?

Authors:  Evangeli S Lampri; Georgios Chondrogiannis; Elli Ioachim; Anna Varouktsi; Antigoni Mitselou; Aggeliki Galani; Evangelos Briassoulis; Panagiotis Kanavaros; Vasiliki Galani
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  Analysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinome.

Authors:  Sami Kilpinen; Kalle Ojala; Olli Kallioniemi
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

7.  Mice deficient in the serine/threonine protein kinase VRK1 are infertile due to a progressive loss of spermatogonia.

Authors:  Matthew S Wiebe; R Jeremy Nichols; Tyler P Molitor; Jill K Lindgren; Paula Traktman
Journal:  Biol Reprod       Date:  2009-08-19       Impact factor: 4.285

8.  Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene.

Authors:  Paul Renbaum; Efrat Kellerman; Ranit Jaron; Dan Geiger; Reeval Segel; Ming Lee; Mary Claire King; Ephrat Levy-Lahad
Journal:  Am J Hum Genet       Date:  2009-07-30       Impact factor: 11.025

Review 9.  A genetic view of laryngeal cancer heterogeneity.

Authors:  María José de Miguel-Luken; Manuel Chaves-Conde; Amancio Carnero
Journal:  Cell Cycle       Date:  2016-03-03       Impact factor: 4.534

10.  Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2.

Authors:  Marta Vázquez-Cedeira; Pedro A Lazo
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.